CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
Original article

CBER-Regulated Products: Shortages and Discontinuations

Neutral
AI Analysis

Summary

FDA guidance on CBER-regulated product shortages and discontinuations, defining shortage as insufficient commercial availability to meet demand.

Importance:2/10
Sentiment:
0.00
regulatoryCBERproduct_shortage

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on July 29, 2026 7:07 PM

Read Original